Visit SOFIE at The Future of Radiopharmaceuticals: Targeted Theranostic Therapeutics (digital conference) on Tuesday, March 14.
Digital Conference,
8:00AM EST // 1:00PM GMT // 2:00PM CET
The Future of Radiopharmaceuticals: Targeted Theranostic Therapeutics (digital conference)
Sherly Mosessian, Chief Scientific Officer of SOFIE is presenting:
Fibroblast Activation Protein (FAP) Inhibitors as Biomarkers in Oncology, Fibrosis, and Cardiovascular Disease
- Current state of FAP as a target for radioligand and non-radioligand interventions
- Clinical development update on fluorine-18 and gallium-68 lead products targeting FAP
- FAPI as a companion diagnostic for patient selection and treatment monitoring in oncology, fibrosis and cardiovascular disease
Radiopharmaceuticals & Imaging
11:05am – 11:35am
EST (Eastern Standard Time, GMT-5)